Trial Profile
A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Acronyms COPE
- Sponsors Pfizer
- 14 Oct 2021 This trial has been completed in France (End Date: 22 May 2012), according to European Clinical Trials Database record.
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 13 Dec 2010 Status changed from recruiting to discontinued as reported in ClinicalTrials.gov.